References
- McKeithan TW, Shima EA, Le Beau MM, . Molecular cloning of the breakpoint junction of a human chromosomal 8;14 translocation involving the T-cell receptor alpha-chain gene and sequences on the 3’ side of MYC. Proc Natl Acad Sci USA 1986;83:6636–6640.
- Lange BJ, Raimondi SC, Heerema N, . Pediatric leukemia/lymphoma with t(8;14)(q24;q11). Leukemia 1992;6:613–618.
- Shima-Rich EA, Harden AM, McKeithan TW, . Molecular analysis of the t(8;14)(q24;q11) chromosomal breakpoint junctions in the T-cell leukemia line MOLT-16. Genes Chromosomes Cancer 1997;20:363–371.
- Langerak AW, Wolvers-Tettero IL, van den Beemd MW, . Immunophenotypic and immunogenotypic characteristics of TCRgammadelta+ T cell acute lymphoblastic leukemia. Leukemia 1999;13:206–214.
- Asnafi V, Beldjord K, Boulanger E, . Analysis of TCR, pT alpha, and RAG-1 in T-acute lymphoblastic leukemias improves understanding of early human T-lymphoid lineage commitment. Blood 2003;101:2693–2703.
- Maziarz RT, Arceci RJ, Bernstein SC, . A gamma delta+ T-cell leukemia bearing a novel t(8;14)(q24;q11) translocation demonstrates spontaneous in vitro natural killer-like activity. Blood 1992;79: 1523–1531.
- Murphy SB, Bowman WP, Abromowitch M, . Results of treatment of advanced-stage Burkitt's lymphoma and B cell (SIg+) acute lymphoblastic leukemia with high-dose fractionated cyclophosphamide and coordinated high-dose methotrexate and cytarabine. J Clin Oncol 1986;4:1732–1739.
- Patte C, Auperin A, Michon J, . The Societe Francaise d’Oncologie Pediatrique LMB89 protocol: highly effective multiagent chemotherapy tailored to the tumor burden and initial response in 561 unselected children with B-cell lymphomas and L3 leukemia. Blood 2001;97:3370–3379.
- Dearden CE, Johnson R, Pettengell R, . Guidelines for the management of mature T-cell and NK-cell neoplasms (excluding cutaneous T-cell lymphoma). Br J Haematol 2011;153: 451–485.
- Nabhan C, Davis N, Bitran JD, . Efficacy and safety of clofarabine in relapsed and/or refractory non-Hodgkin lymphoma, including rituximab-refractory patients. Cancer 2011;117:1490–1497.
- Locatelli F, Testi AM, Bernardo ME, . Clofarabine, cyclophosphamide and etoposide as single-course re-induction therapy for children with refractory/multiple relapsed acute lymphoblastic leukaemia. Br J Haematol 2009;147:371–378.
- Hijiya N, Thomson B, Isakoff MS, . Phase 2 trial of clofarabine in combination with etoposide and cyclophosphamide in pediatric patients with refractory or relapsed acute lymphoblastic leukemia. Blood 2011;118:6043–6049.
- Asselin BL, Devidas M, Wang C, . Effectiveness of high-dose methotrexate in T-cell lymphoblastic leukemia and advanced-stage lymphoblastic lymphoma: a randomized study by the Children's Oncology Group (POG 9404). Blood 2011;118:874–883.
- Moricke A, Reiter A, Zimmermann M, . Risk-adjusted therapy of acute lymphoblastic leukemia can decrease treatment burden and improve survival: treatment results of 2169 unselected pediatric and adolescent patients enrolled in the trial ALL-BFM 95. Blood 2008;111:4477–4489.
- Hahn T, Wall D, Camitta B, . The role of cytotoxic therapy with hematopoietic stem cell transplantation in the therapy of acute lymphoblastic leukemia in children: an evidence-based review. Biol Blood Marrow Transplant 2005;11:823–861.